[go: up one dir, main page]

WO2008078729A1 - Method for improving dissolution property - Google Patents

Method for improving dissolution property Download PDF

Info

Publication number
WO2008078729A1
WO2008078729A1 PCT/JP2007/074784 JP2007074784W WO2008078729A1 WO 2008078729 A1 WO2008078729 A1 WO 2008078729A1 JP 2007074784 W JP2007074784 W JP 2007074784W WO 2008078729 A1 WO2008078729 A1 WO 2008078729A1
Authority
WO
WIPO (PCT)
Prior art keywords
dissolution property
improving dissolution
azelnidipine
olmesartan medoxomil
improving
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2007/074784
Other languages
French (fr)
Japanese (ja)
Inventor
Ikumasa Ohno
Ryoichi Hayakawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Daiichi Sankyo Co Ltd
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Priority to JP2008551107A priority Critical patent/JP5241512B2/en
Publication of WO2008078729A1 publication Critical patent/WO2008078729A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Disclosed is a method for improving dissolution property of a solid preparation containing olmesartan medoxomil and azelnidipine. Specifically, olmesartan medoxomil and azelnidipine are separately arranged so that they are not in contact with each other.
PCT/JP2007/074784 2006-12-26 2007-12-25 Method for improving dissolution property Ceased WO2008078729A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2008551107A JP5241512B2 (en) 2006-12-26 2007-12-25 Dissolution improvement method

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006349474 2006-12-26
JP2006-349474 2006-12-26

Publications (1)

Publication Number Publication Date
WO2008078729A1 true WO2008078729A1 (en) 2008-07-03

Family

ID=39562518

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2007/074784 Ceased WO2008078729A1 (en) 2006-12-26 2007-12-25 Method for improving dissolution property

Country Status (4)

Country Link
JP (1) JP5241512B2 (en)
KR (1) KR20090094285A (en)
TW (1) TWI488658B (en)
WO (1) WO2008078729A1 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010107081A1 (en) * 2009-03-19 2010-09-23 第一三共株式会社 Solid preparation stably preserved in packaging
JP2011225537A (en) * 2010-03-31 2011-11-10 Daiichi Sankyo Co Ltd Production method for solid preparation
JP2014224099A (en) * 2013-04-15 2014-12-04 株式会社三和化学研究所 Olmesartan medoxomil-containing pharmaceutical composition
JP2015511635A (en) * 2012-03-30 2015-04-20 デウン ファーマシューティカル カンパニー リミテッド Pharmaceutical composition comprising olmesartan medoxomil and rosuvastatin or a salt thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004067003A1 (en) * 2003-01-31 2004-08-12 Sankyo Company, Limited Medicine for prevention of and treatment for arteriosclerosis and hypertension
JP2006298764A (en) * 2005-04-15 2006-11-02 Sankyo Co Ltd Composite useful for hypertension treatment
WO2007001067A2 (en) * 2005-06-27 2007-01-04 Daiichi Sankyo Company, Limited Solid dosage form comprising an angiotensin ii receptor antagonist and a calcium channel blocker

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE481090T1 (en) * 1998-07-28 2010-10-15 Takeda Pharmaceutical EASILY DISSOLVING SOLID PREPARATION
US20060034913A1 (en) * 2004-08-13 2006-02-16 James Gaede Multiplex drug delivery device
EP1814527B2 (en) * 2004-11-05 2020-11-18 Boehringer Ingelheim International GmbH Bilayer tablet comprising telmisartan and amlodipine
JP5063370B2 (en) * 2005-06-27 2012-10-31 第一三共株式会社 Method for preparing wet granulated pharmaceutical
US20080279942A1 (en) * 2005-06-27 2008-11-13 Takeshi Hamaura Pharmaceutical Preparation Containing an Angiotensin II Receptor Antagonist and a Calcium Channel Blocker

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004067003A1 (en) * 2003-01-31 2004-08-12 Sankyo Company, Limited Medicine for prevention of and treatment for arteriosclerosis and hypertension
JP2006298764A (en) * 2005-04-15 2006-11-02 Sankyo Co Ltd Composite useful for hypertension treatment
WO2007001067A2 (en) * 2005-06-27 2007-01-04 Daiichi Sankyo Company, Limited Solid dosage form comprising an angiotensin ii receptor antagonist and a calcium channel blocker

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MATSUMOTO M.: "Yakuzaigaku Manual", vol. 1ST ED., 1989, NANZANDO CO., LTD., HAKKO, pages: 114 *
OKANO T.: "Shin.Yakuzaigaku Soron", vol. 3RD ED., 1987, NANOKODO CO., LTD., HAKKO, pages: 134 - 145 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010107081A1 (en) * 2009-03-19 2010-09-23 第一三共株式会社 Solid preparation stably preserved in packaging
JPWO2010107081A1 (en) * 2009-03-19 2012-09-20 第一三共株式会社 Solid formulation stably stored by packaging
JP2011225537A (en) * 2010-03-31 2011-11-10 Daiichi Sankyo Co Ltd Production method for solid preparation
JP2015511635A (en) * 2012-03-30 2015-04-20 デウン ファーマシューティカル カンパニー リミテッド Pharmaceutical composition comprising olmesartan medoxomil and rosuvastatin or a salt thereof
JP2014224099A (en) * 2013-04-15 2014-12-04 株式会社三和化学研究所 Olmesartan medoxomil-containing pharmaceutical composition

Also Published As

Publication number Publication date
JPWO2008078729A1 (en) 2010-04-30
JP5241512B2 (en) 2013-07-17
TW200835525A (en) 2008-09-01
KR20090094285A (en) 2009-09-04
TWI488658B (en) 2015-06-21

Similar Documents

Publication Publication Date Title
GB2454620B (en) Solid dosage form of olmesartan medoxomil and amlodipine
AU2009240389A8 (en) Nanoemulsions for treating fungal, yeast and mold infections
MX285041B (en) Fuel compositions comprising farnesane and farnesane derivatives and method of making and using same.
WO2008005705A3 (en) Metal-containing formulations and methods of use
WO2007146965A3 (en) Compounds for the treatment of periodontal disease
SI2044076T1 (en) Process for the preparation of asenapine and intermediate products used in said process.
IL207792A0 (en) Methods, dosage forms, and kits for administering ziprasidone without food
WO2008027600A3 (en) Imatinib compositions
EP1993322A4 (en) Ultrasonic sensor, and its manufacturing method
WO2008078726A1 (en) Solid preparation
WO2010069335A3 (en) Diagnosis of endometritis
WO2008078729A1 (en) Method for improving dissolution property
WO2008021135A8 (en) Syneretic composition, associated method and article
WO2007099555A3 (en) Pharmaceutical tablet compositions containing irbesartan
EP2074258A4 (en) Fiberboards, uses and methods of preparation thereof
WO2009053742A3 (en) Salts of nefopam and their use in therapy
WO2009113091A3 (en) Pharmaceutical compositions comprising valsartan
WO2008078727A1 (en) Pharmaceutical composition having improved dissolution property
WO2008073317A3 (en) Cytarabine for treatment of glioma
GB2435262B (en) Method, composition and articles
GB0607562D0 (en) Method, composition and use
WO2008074461A3 (en) Fluorescent nanoparticles
GB0607354D0 (en) Agent, Composition And Method
GB201018110D0 (en) Solid dosage form of olmesartan medoxomil, amiodipine and hydrochlorothiazide
HK1127282B (en) Solid dosage form of olmesartan medoxomil and amlodipine

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07860013

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2008551107

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 1020097012652

Country of ref document: KR

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07860013

Country of ref document: EP

Kind code of ref document: A1